--- title: "Brief News: Legend Biotech's revenue grew strongly in the fourth quarter" type: "News" locale: "en" url: "https://longbridge.com/en/news/278671390.md" description: "Legend Biotech Corporation announced that thanks to the growth of the ciltacabtagene autoleucel cancer therapy, fourth-quarter revenue increased by 64% year-on-year to $306 million, driving the company to achieve an adjusted profit of $2.5 million. Revenue from the collaboration with Janssen grew by 65%, with the drug launched in 14 markets and expected to become profitable by 2025. Under GAAP, the fourth-quarter loss was $30.9 million. On Tuesday, the stock price rose by 2.2%, closing at $19.56" datetime: "2026-03-11T07:02:03.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/278671390.md) - [en](https://longbridge.com/en/news/278671390.md) - [zh-HK](https://longbridge.com/zh-HK/news/278671390.md) --- # Brief News: Legend Biotech's revenue grew strongly in the fourth quarter **Legend Biotech Corporation** (LEGN.US) announced on Tuesday that it achieved strong double-digit revenue growth in the fourth quarter of last year, driven by robust growth of its core product Carvykti cancer therapy, leading the company to report adjusted profitability for the quarter. Legend Biotech's fourth-quarter revenue increased by 64% year-over-year, rising from $187 million in the same period last year to $306 million. Revenue from its collaboration with U.S. pharmaceutical company Janssen for Carvykti grew by 65% year-over-year, from $168 million to $278 million. Legend Biotech stated that Carvykti is currently in use at 294 locations across 14 markets worldwide, and the drug is expected to achieve profitability by 2025. The company reported an adjusted profit of $2.5 million for the quarter (excluding certain non-cash items), compared to a loss of $59 million in the same period last year. However, under U.S. Generally Accepted Accounting Principles (GAAP), it recorded a loss of $30.9 million in the fourth quarter, compared to a profit of $26.4 million in the same period last year. On Tuesday, Legend Biotech's stock price rose by 2.2% in the New York market, closing at $19.56, with the stock down approximately 43% over the past 52 weeks. _Yang Ge_ ### Related Stocks - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [XLV.US](https://longbridge.com/en/quote/XLV.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LEGN.US](https://longbridge.com/en/quote/LEGN.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [BUZZ-Allogene tumbles on $175 mln stock offering after cancer therapy data](https://longbridge.com/en/news/282722450.md) - [BUZZ-Street View: Analysts upbeat on Revolution pancreatic cancer drug](https://longbridge.com/en/news/282702171.md) - [](https://longbridge.com/en/news/282578794.md) - [Gilead to Buy Cancer Biotech Tubulis in $5B Deal](https://longbridge.com/en/news/282092620.md) - [C4 Therapeutics Deepens Roche Alliance To Target Breakthrough Cancer Therapies](https://longbridge.com/en/news/282214646.md)